Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Jan P.C. Heiligers"'
Autor:
Pramod R. Saxena, David Centurión, Carlos M. Villalón, Ingrid M. Garrelds, Udayasankar Arulmani, Jan P.C. Heiligers
Publikováno v:
Cephalalgia, 25(11), 1082-1090. SAGE Publications Ltd
Migraine is a common neurological disorder that is associated with an increase in plasma calcitonin gene-related peptide (CGRP) levels. CGRP, a potent vasodilator released from the activated trigeminal sensory nerves, dilates intracranial blood vesse
Autor:
Jan P.C. Heiligers, Martin P Schuijt, Carlos M. Villalón, Edwin W Willems, Udayasankar Arulmani, Pramod R. Saxena
Publikováno v:
Basic & Clinical Pharmacology & Toxicology, 94, 291-297. Wiley-Blackwell
Several studies suggest that a calcitonin gene-related peptide (CGRP) receptor antagonist may have antimigraine properties, most probably via the inhibition of CGRP-induced cranial vasodilatation. We recently showed that the novel selective CGRP rece
Autor:
Pramod R. Saxena, Carlos M. Villalón, Jan P.C. Heiligers, Araceli Sánchez-López, Udayasankar Arulmani, Ingrid M. Garrelds, Edwin W Willems
Publikováno v:
Cephalalgia, 24, 717-727. SAGE Publications Ltd
It is suggested that during a migraine attack capsaicin-sensitive trigeminal sensory nerves release calcitonin gene related peptide (CGRP), resulting in cranial vasodilatation and central nociception. Hence, inhibition of trigeminal CGRP release may
Autor:
Udayasankar Arulmani, Henri Doods, Pramod R. Saxena, Carlos M. Villalón, Jan P.C. Heiligers, Kapil Kapoor, Ingrid M. Garrelds, Edwin W Willems
Publikováno v:
British Journal of Pharmacology. 140:329-338
textabstract1. Calcitonin gene-related peptide (CGRP), a potent vasodilator released from capsaicin-sensitive trigeminal sensory nerves, seems to be involved in the pathogenesis of migraine. Hence, CGRP receptor antagonists may serve as a novel treat
Autor:
Edwin W Willems, Carlos M. Villalón, Henri Doods, Pramod R. Saxena, Udayasankar Arulmani, Jan P.C. Heiligers, Kapil Kapoor
Publikováno v:
European Journal of Pharmacology, 475, 69-77. Elsevier
Calcitonin gene related peptide (CGRP) seems to be involved in the pathogenesis of migraine, since plasma CGRP levels increase during the headache phase. In the present study, we investigated the effects of a novel CGRP receptor antagonist, BIBN4096B
Autor:
Dirk-Jan G.M. Duncker, Pramod R. Saxena, Jan P.C. Heiligers, Marieke E. van Meeteren, Ingrid M. Garrelds, Maarten A C Meijssen, F.J. Zijlstra
Publikováno v:
Digestive Diseases and Sciences. 47:2231-2236
The aim of this study was to assess whether colitis induced by dextran sulfate sodium (DSS; 10% in tap water for 7 days) in BALB/c mice is associated with changes in intestinal blood flow. After anaesthesia, systemic hemodynamic variable and regional
Autor:
Edwin W Willems, Marjo Trion, Carlos M. Villalón, Jan P.C. Heiligers, Peter De Vries, Pramod R. Saxena
Publikováno v:
British Journal of Pharmacology. 127:1263-1271
Vasoconstriction of carotid arteriovenous anastomoses may be involved in the therapeutic action of acutely acting anti-migraine agents, including the triptans and ergot alkaloids. While 5-HT1B/1D receptors mediate the effect of triptans, ergotamine a
Publikováno v:
British Journal of Pharmacology. 127:405-412
It has previously been shown that the antimigraine drug sumatriptan constricts porcine carotid arteriovenous anastomoses via 5-HT1-like receptors, identical to 5-HT1B/1D receptors. The recent availability of silent antagonists selective for the 5-HT1
Publikováno v:
European Journal of Pharmacology, 351, 193-201. Elsevier
In previous studies, we have shown that several 5-HT1B/1D receptor agonists, including sumatriptan, potently constrict porcine carotid arteriovenous anastomoses. This effect seems to be of high predictive value for antimigraine activity. In the prese
Publikováno v:
British Journal of Pharmacology. 123:1561-1570
1. It was previously shown that porcine cranial arteriovenous anastomoses (AVAs) constrict to 5-hydroxytryptamine (5-HT), ergotamine, dihydroergotamine, as well as sumatriptan and that sumatriptan acts exclusively via 5-HT1B/1D receptors. The present